CN114195706A - 一种n-三苯基亚胺吡啶配体及其镍和钯配合物及配合物的制备与应用 - Google Patents

一种n-三苯基亚胺吡啶配体及其镍和钯配合物及配合物的制备与应用 Download PDF

Info

Publication number
CN114195706A
CN114195706A CN202111259158.7A CN202111259158A CN114195706A CN 114195706 A CN114195706 A CN 114195706A CN 202111259158 A CN202111259158 A CN 202111259158A CN 114195706 A CN114195706 A CN 114195706A
Authority
CN
China
Prior art keywords
triphenylimine
pyridine
complex
triphenyliminepyridine
palladium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111259158.7A
Other languages
English (en)
Inventor
常贯儒
亓昭鹏
陈龙
王俊波
邬堃
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Huangshan University
Original Assignee
Huangshan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huangshan University filed Critical Huangshan University
Priority to CN202111259158.7A priority Critical patent/CN114195706A/zh
Publication of CN114195706A publication Critical patent/CN114195706A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/53Nitrogen atoms
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/18Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms
    • B01J31/1805Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms the ligands containing nitrogen
    • B01J31/181Cyclic ligands, including e.g. non-condensed polycyclic ligands, comprising at least one complexing nitrogen atom as ring member, e.g. pyridine
    • B01J31/1815Cyclic ligands, including e.g. non-condensed polycyclic ligands, comprising at least one complexing nitrogen atom as ring member, e.g. pyridine with more than one complexing nitrogen atom, e.g. bipyridyl, 2-aminopyridine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2/00Preparation of hydrocarbons from hydrocarbons containing a smaller number of carbon atoms
    • C07C2/02Preparation of hydrocarbons from hydrocarbons containing a smaller number of carbon atoms by addition between unsaturated hydrocarbons
    • C07C2/04Preparation of hydrocarbons from hydrocarbons containing a smaller number of carbon atoms by addition between unsaturated hydrocarbons by oligomerisation of well-defined unsaturated hydrocarbons without ring formation
    • C07C2/06Preparation of hydrocarbons from hydrocarbons containing a smaller number of carbon atoms by addition between unsaturated hydrocarbons by oligomerisation of well-defined unsaturated hydrocarbons without ring formation of alkenes, i.e. acyclic hydrocarbons having only one carbon-to-carbon double bond
    • C07C2/08Catalytic processes
    • C07C2/14Catalytic processes with inorganic acids; with salts or anhydrides of acids
    • C07C2/20Acids of halogen; Salts thereof ; Complexes thereof with organic compounds
    • C07C2/22Metal halides; Complexes thereof with organic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/30Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/333Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
    • C07C67/343Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C67/347Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by addition to unsaturated carbon-to-carbon bonds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/04Nickel compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/04Nickel compounds
    • C07F15/045Nickel compounds without a metal-carbon linkage
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08FMACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F10/00Homopolymers and copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08FMACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F110/00Homopolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond
    • C08F110/04Monomers containing three or four carbon atoms
    • C08F110/06Propene
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/20Olefin oligomerisation or telomerisation
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/02Compositional aspects of complexes used, e.g. polynuclearity
    • B01J2531/0238Complexes comprising multidentate ligands, i.e. more than 2 ionic or coordinative bonds from the central metal to the ligand, the latter having at least two donor atoms, e.g. N, O, S, P
    • B01J2531/0241Rigid ligands, e.g. extended sp2-carbon frameworks or geminal di- or trisubstitution
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80Complexes comprising metals of Group VIII as the central metal
    • B01J2531/84Metals of the iron group
    • B01J2531/847Nickel
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2531/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • C07C2531/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • C07C2531/22Organic complexes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Pyridine Compounds (AREA)

Abstract

本发明属于乙烯聚合催化技术领域,具体涉及一种N‑三苯基亚胺吡啶配体及其镍和钯配合物及镍和钯配合物的制备与应用。N‑三苯基亚胺吡啶配体的结构式如式Ⅰ所示:
Figure DDA0003325017140000011
其中R为氢‑H、甲基‑CH3、氯‑Cl、氟‑F和叔丁基‑tBu中的任意一种。利用该N‑三苯基亚胺吡啶配体制备的N‑三苯基亚胺吡啶镍配合物和N‑三苯基亚胺吡啶钯配合物,可以作为烯烃聚合反应的催化剂,对乙烯、丙烯或α‑烯烃中任意一种或多种进行催化聚合,得到低分子量和高度支化的聚烯烃或烯烃‑丙烯酸酯类共聚物,在生产功能化的聚烯烃上具有广阔的应用前景。

Description

一种N-三苯基亚胺吡啶配体及其镍和钯配合物及配合物的制 备与应用
技术领域
本发明属于乙烯聚合催化技术领域,具体涉及一种N-三苯基亚胺吡啶配体及其镍和钯配合物及镍和钯配合物的制备与应用。
技术背景
由于独特的低粘度、低密度、良好的流变性及末端可功能化修饰等优点,高支化乙烯低聚物在很多领域都有广泛的应用,如作为润滑剂、增韧剂、增溶剂、交联剂、表面改性剂等,作为功能性添加剂具有很高的附加值。具有超支化微结构的低分子量乙烯低聚物通常很难通过传统的催化工艺制备。传统多活性中心的Ziegler-Natta催化体系特点是所制备的支化聚乙烯通常支链较短,且支链分布不均一,分子量分布较宽。
聚α-烯烃合成润滑油具有优异的黏温性能和低温流动性,但主要存在工艺流程复杂、原料价格高和目标产物收率较低,导致生产成本居高不下。如果能采用廉价的原料如丙烯、乙烯,通过开发新型催化剂,直接低聚生产聚烯烃润滑油,不仅能简化合成工艺,降低生产成本,还能减少环境污染,提高聚乙烯材料的附加值。自从Brookhart教授研究发现α-二亚胺钯催化剂具有超强的链行走能力,能够催化乙烯链行走聚合能得到超支化、油状的聚乙烯产物。但是产物的黏度太高,低温流动性差,使得早期所得HBPE只能用作润滑油的黏度指数改进剂。虽然利用α-二亚胺钯催化乙烯低聚直接制备了油状的HBPE,并且具有合成润滑油应用的前景,但是也存在一些问题。首先,产物聚乙烯油的低温流动性有待进一步提高。其次,产物的支化结构以甲基短支链为主,长支链含量低,与相同分子量的聚α-烯烃润滑油相比粘度指数偏低。
为改善聚烯烃材料的表面性、混溶性,黏附力、流变性及与其它高分子材料的相容性和共混性等重要性能,将极性基团引入到聚烯烃链结构中,拓宽聚烯烃的功能,增加聚烯烃的价值,成为烯烃聚合领域的重要研究方向。
工业上目前广泛研究与应用的前过渡金属催化剂不能够催化烯烃与极性单体共聚,主要是因为极性官能团容易毒化金属中心,如氧,氮,膦等杂原子,使催化剂失活。极性单体的存在易于形成极性基团螯合与加快链转移反应,导致共聚反应活性低、极性单体插入率低、以及聚合物分子量低等问题。
发明内容
为了解决上述问题,本发明的目的之一在于提供一种N-三苯基亚胺吡啶配体,该N-三苯基亚胺吡啶配体的结构式如式(Ⅰ)所示:
Figure RE-GDA0003391003000000021
其中,R为氢-H、甲基-CH3、氯-Cl、氟-F和叔丁基-tBu中任意一种。
本发明还提供上述一种N-三苯基亚胺吡啶配体的制备方法,包括以下步骤:
S1.在圆底烧瓶中放入0.5-4N的ZnCl2、10-50N的2-乙酰吡啶和3-10mL 冰醋酸的悬浮液,加入0.8-3N的2,6-二-(4-R-苯基)-4-甲基苯胺同类物,加热搅拌回流1-6h,冷却至室温;N为当量值;
S2.S1中溶液冷却至室温,沉淀出亮黄色固体,过滤并分离所述亮黄色固体,依次使用乙酸和乙醚洗涤后,在真空下干燥得到橘红色提纯固体;
S3.将所述橘红色提纯固体放入盛有10-60mL二氯甲烷的圆底烧瓶中,加入1-6N草酸钾水溶液3-20mL,并以1000-2000r/min速度搅拌30-80min;
S4.搅拌后溶液进行两相分离,水洗有机溶剂层,并用MgSO4干燥除去有机溶剂层水,再减压过滤;
S5.过滤后在真空干燥箱中去除溶剂,得到产物为黄色粉末或黄色油性产物,即为所需的N-三苯基亚胺吡啶配体。
该制备方法的反应过程为:
Figure RE-GDA0003391003000000031
优选的,所述2,6-二-(4-R-苯基)-4-甲基苯胺同类物的制备方法,具体步骤为:
S11.氮气气氛下,将10-30N的4-R-苯基硼酸、5-20N的2,6-二溴-4-甲基-苯胺、1-2N的Pd(PPh3)4和30-100N的K2 CO3的混合物加入四氢呋喃与水的混合物液中,再将混合物液加热至65-80℃,搅拌18-36h;四氢呋喃与水以4:1~6:1体积比混合;
S12.将反应后的混合物液转移到旋转蒸发器中,去除溶剂,并用二氯甲烷提取残渣,继续转移到分液漏斗,加入水,震荡后静置分离出下层有机相,并用MgSO4干燥所述有机相;
S13过滤除去MgSO4固体,将有机相转移到旋转蒸发器中浓缩,浓缩液通过硅胶柱层析(硅胶:PE/DCM=1:1)分离,分离得到的第二个白色组分即为2,6-二-(4-R-苯基)-4-甲基苯胺同类物。
本发明的目的之二在于提供一种N-三苯基亚胺吡啶镍配合物,所述配合物由上述的N-三苯基亚胺吡啶配体与镍化合物形成,所述镍化合物为 (DME)NiBr2,所述配合物的结构式如式(Ⅱ)所示:
Figure RE-GDA0003391003000000032
其中,R为氢-H、甲基-CH3、氯-Cl、氟-F和叔丁基-tBu中任意一种。
优选的,N-三苯基亚胺吡啶镍配合物制备方法为:在氮气氛围下,将N-三苯基亚胺吡啶配体和(DME)NiBr2按摩尔比1:0.5-2混合并溶解在惰性溶剂中,室温下搅拌反应6-24h;搅拌结束后,在旋转蒸发器皿中采用减压蒸馏方式得到固体产物,并将所述固体产物用乙烷洗涤,真空干燥得到所需的N-三苯基亚胺吡啶镍配合物。
反应过程如下:
Figure RE-GDA0003391003000000041
优选的,所述惰性溶剂为二氯甲烷或三氯甲烷。
本发明的目的之三在于提供一种N-三苯基亚胺吡啶钯配合物,所述配合物由上述的N-三苯基亚胺吡啶配体与钯化合物形成,所述钯化合物为 (COD)PdMeCl,所述配合物的结构式如式(Ⅲ)所示:
Figure RE-GDA0003391003000000042
其中,R为氢-H、甲基-CH3、氯-Cl、氟-F和叔丁基-tBu中任意一种。
优选的,N-三苯基亚胺吡啶钯配合物制备方法为:在氮气氛围下,将N- 三苯基亚胺吡啶配体和(COD)PdMeCl按摩尔比1:0.5-2混合并溶解在惰性溶剂中,室温下搅拌反应12-48h;搅拌结束后,在旋转蒸发器皿中采用减压蒸馏方式直至观察到开始出现固体产物;停止旋蒸,在剩余惰性溶剂和固体产物中加入10-50ml乙醚稀释,得到黄色沉淀物;过滤并真空干燥该黄色沉淀物,即得到所需的N-三苯基亚胺吡啶钯配合物。
反应过程为:
Figure RE-GDA0003391003000000051
优选的,所述惰性溶剂为二氯甲烷或三氯甲烷。
本发明的目的之四在于提供上述N-三苯基亚胺吡啶镍配合物和上述N-三苯基亚胺吡啶钯配合物作为烯烃聚合反应的催化剂的应用。
优选的,所述应用为:N-三苯基亚胺吡啶镍配合物对乙烯、丙烯或α-烯烃中任意一种或多种进行催化聚合,得到低分子量(数均分子量Mn在1000- 2000g/mol)和具有甲基支和大量的长链支或支上支(最高比例达40%)微观结构的超支化(枝度高在69-100/1000C)聚烯烃。
优选的,所述应用为:N-三苯基亚胺吡啶钯配合物对乙烯、丙烯或α-烯烃中任意一种或多种进行催化聚合,得到低分子量(数均分子量Mn在260- 800g/mol),具有大量的长链支或支上支(高达87%)微观结构的超支化(枝度高在127-165/1000C)的乙烯齐聚物。
优选的,所述N-三苯基亚胺吡啶钯配合物对烯烃与丙烯酸酯类化合物进行催化共聚,获得高插入比(约为10mol%)的、低分子量(260~787g/mol) 的烯烃-丙烯酸酯类。
优选的,所述丙烯酸酯类化合物为丙烯酸甲酯。
本发明的有益效果在于:
1.本发明提供的N-三苯基亚胺吡啶配体为含2,6-二-(4-R-苯基)-4-甲基的亚胺吡啶配体,并基于其制备了N-三苯基亚胺吡啶Ni(II)、Pd(II)配合物,通过引入2,6-二-(4-R-苯基)-4-甲基苯胺,两个分子结构中的邻芳基都偏离了金属中心,不能对金属中心的轴向位置提供有效的屏蔽,从而导致聚合过程中快速的链转移或者链行走,进而获得低分子量的超支化无定型聚烯烃。
2.采用传统的催化方法很难制备出具有超支化结构的低分子量乙烯低聚物。本发明提供了一种简单高效合成一系列N-三苯基亚胺吡啶配体及相应的带有不同电子效应(H,Me,t-Bu,F,Cl)的远端共轭取代基的Ni(II)和Pd(II)配合物,这些 N-三苯基亚胺吡啶Ni(II)配合物和N-三苯基亚胺吡啶Pd(II)配合物作为烯烃齐聚或烯烃与丙烯酸酯类共聚反应中的催化剂,能够得到具有大量长链支或支上支结构组成的超支化、低分子量、高插入比的极性功能化聚烯烃或烯烃-丙烯酸酯类共聚物,在生产功能化聚烯烃上具有广阔的应用前景。
3.本发明提供的N-三苯基亚胺吡啶镍(II)配合物和钯(II)配合物可以作为烯烃聚合反应的催化剂,由于其供电子和大位阻效应,部分屏蔽了金属中心轴向结合位点,在与丙烯酸酯的结合中表现出了很高的效率,能有效地促进烯烃与丙烯酸酯类的共聚反应,得到高度支化的较高插入比的极性功能化烯烃-丙烯酸酯类共聚物。另外现有技术中对调节聚乙烯分支密度较难,本发明提供的N-三苯基亚胺吡啶钯(Ⅱ)配合物与现有的Pd(II)催化剂相比,可产生更高的支链聚乙烯和E-MA共聚物。
附图说明
图1A-E分别对应为N-三苯基亚胺吡啶配体L1-L5的核磁氢谱。
图2A-E分别对应为N-三苯基亚胺吡啶配体Ni1-Ni5的质谱。
图3A为N-三苯基亚胺吡啶钯配合物Pd1的核磁氢谱;图3B N-三苯基亚胺吡啶钯配合物Pd1的质谱。
图4A为N-三苯基亚胺吡啶钯配合物Pd2的核磁氢谱;图4B为N-三苯基亚胺吡啶钯配合物Pd2的质谱。
图5A为N-三苯基亚胺吡啶钯配合物Pd3的核磁氢谱;图5B为N-三苯基亚胺吡啶钯配合物Pd3的质谱。
图6A为N-三苯基亚胺吡啶钯配合物Pd4的核磁氢谱;图6B为N-三苯基亚胺吡啶钯配合物Pd4的质谱。
图7A为N-三苯基亚胺吡啶钯配合物Pd5的核磁氢谱;图7B为N-三苯基亚胺吡啶钯配合物Pd5的质谱。
上述核磁共振所用的氘代溶剂在使用前经过干燥和蒸馏,氢谱由JNM- ECZ600R光谱仪在室温下记录。
上述通过(ESI)LCMS-2010A来完成N-三苯基亚胺吡啶配体L1、L2、L3、 L4和L5的质谱分析,通过Auto flex Speed MALDI-TOF MS来完成N-三苯基亚胺吡啶镍配合物Ni1、Ni2、Ni3、Ni4和Ni5和N-三苯基亚胺吡啶钯配合物Pd1、 Pd2、Pd3、Pd4和Pd5的质谱分析。
具体实施方式
除非另有说明,本文中所使用的术语均具有本领域技术人员常规理解的含义。
下面结合实施例对本发明的技术方案做出更为具体的说明:
实施例1:
一种N-三苯基亚胺吡啶配体L1,其结构式如下所示:
Figure RE-GDA0003391003000000071
S1.在圆底烧瓶中放入ZnCl2(0.34g,2.5mmol)、2-乙酰吡啶(20.0mmol) 和5mL冰醋酸形成悬浮液,加入2mmol的2,6-二-苯基-4-甲基苯胺,加热搅拌回流4h;
S2.S1中溶液冷却至室温,沉淀出亮黄色固体,过滤并分离该亮黄色固体,依次使用5mL乙酸洗涤三遍、5mL乙醚洗涤5遍,去除残留的乙酸后,在真空下干燥得到亮黄色提纯固体;
S3.将上述亮黄色提纯固体放入盛有30mL二氯甲烷的圆底烧瓶中,加入草酸钾(0.41g,2.2mmol)水溶液5mL,并快速搅拌1h;
S4.搅拌后溶液进行两相分离,20mL水洗有机溶剂层三遍,并用MgSO4干燥除去有机溶剂层水,再减压过滤;
S5.过滤后在真空去除溶剂,得到黄色粉末产品,在高真空下干燥,即得到目标产物N-三苯基亚胺吡啶L1。
本申请制备L1所得质量0.27g,产率75%。L1的氢谱和质谱如下:
1H NMR(600MHz,CDCl3)δ8.49(d,J=4.4Hz,1H,Ar-H),7.98(d,J=7.9Hz, 1H,Ar-H),7.68(t,J=7.5Hz,1H,Ar-H),7.46(d,J=7.6Hz,4H,Ar-H),7.29(t,J=7.1 Hz,4H,Ar-H),7.26(s,1H,Ar-H),7.25(s,2H,Ar-H),7.21(t,J=7.3Hz,2H,Ar-H), 2.48(s,3H,CH3),1.89(s,3H,Ar-C(CH3)=N).13C NMR(151MHz,CDCl3)δ 167.21(C=N),156.29,148.27,144.17,140.48,136.26,133.44,131.94,130.48,129.37, 127.92,126.65,124.48,121.39,20.94(CH3),17.90(Ar-C(CH3)=N).
APCI-MS(m/z):calcd for C26H23N2:363.1856,Found,363.1842,[M+H]+.
实施例2:
一种N-三苯基亚胺吡啶配体L2,其结构式如下所示:
Figure RE-GDA0003391003000000081
L2的制备方法同L1,不同在于将步骤S1中2,6-二-苯基-4-甲基苯胺替换为2,6-二-(4-甲基-苯基)-4-甲基苯胺。
本申请制备L2所得质量0.30g,产率78%。L2的氢谱和质谱如下:
1H NMR(600MHz,CDCl3)δ8.49(d,J=4.5Hz,1H,Ar-H),8.02(d,J=8.0Hz, 1H,Ar-H),7.68(td,J=7.9,1.4Hz,1H,Ar-H),7.32(d,J=7.9Hz,4H,Ar-H),7.25– 7.23(m,1H,Ar-H),7.18(s,2H,Ar-H),7.06(d,J=7.9Hz,4H,Ar-H),2.43(s,3H,CH3), 2.29(s,6H,Ar-CH3),1.87(s,3H,Ar-C(CH3)=N).
APCI-MS(m/z):calcd for C28H27N2:391.2169,Found,391.2159,[M+H]+.
实施例3:
一种N-三苯基亚胺吡啶配体L3,其结构式如下所示:
Figure RE-GDA0003391003000000091
L3的制备方法同L1,不同在于将步骤S1中2,6-二-苯基-4-甲基苯胺替换为2,6-二-(4-氟基-苯基)-4-甲基苯胺。
本申请制备L3所得质量0.32g,产率80%。L3的氢谱和质谱如下:
1H NMR(600MHz,CDCl3)δ8.50(d,J=4.5Hz,1H,Ar-H),7.97(d,J=8.0Hz, 1H,Ar-H),7.72–7.63(m,1H,Ar-H),7.42–7.38(m,4H,Ar-H),7.27–7.25(m,1H,Ar- H),7.19(s,2H,Ar-H),6.99–6.94(m,4H,Ar-H),2.44(s,3H,CH3),1.88(s,3H,Ar- C(CH3)=N).13C NMR(151MHz,CDCl3)δ167.52(C=N),162.62,161.00,155.95, 148.45,144.23,136.38,136.31,136.30,133.64,130.99,130.93,130.88,130.47, 124.73,121.18,114.96,114.82,20.89(CH3),17.92(Ar-C(CH3)=N).19F NMR(565 MHz,CDCl3)δ-113.14–-117.42(m).
APCI-MS(m/z):calcd for C26H21F2N2:399.1667,Found,399.1650,[M+H]+.
实施例4:
一种N-三苯基亚胺吡啶配体L4,其结构式如下所示:
Figure RE-GDA0003391003000000092
L4的制备过程同L1,不同在于将步骤S1中2,6-二-苯基-4-甲基苯胺替换为2,6-二-(4-氯基-苯基)-4-甲基苯胺。
本申请制备L4所得质量0.34g,产率78%。L4的氢谱和质谱如下:
1H NMR(600MHz,CDCl3)δ8.50(d,J=4.4Hz,1H,Ar-H),7.98(d,J=7.9Hz, 1H,Ar-H),7.69(td,J=7.8,1.5Hz,1H,Ar-H),7.37(d,J=8.4Hz,4H,Ar-H),7.28–7.26(m,1H,Ar-H),7.23(d,J=8.5Hz,4H,Ar-H),7.18(s,2H,Ar-H),2.43(s,3H,CH3), 1.87(s,3H,Ar-C(CH3)=N).13C NMR(151MHz,CDCl3)δ167.61(C=N),155.79, 148.53,148.47,144.17,138.75,136.43,133.77,132.71,130.78,130.65,130.63, 128.22,128.18,124.85,124.80,121.16,20.89(CH3),17.87(Ar-C(CH3)=N).
APCI-MS(m/z):calcd for C26H21Cl2N2:431.1076,Found,431.1068,[M+H]+.
实施例5:
一种N-三苯基亚胺吡啶配体L5,其结构式如下所示:
Figure RE-GDA0003391003000000101
L5的制备过程同L1,不同在于将步骤S1中2,6-二-苯基-4-甲基苯胺替换为2,6-二-(4-叔丁基-苯基)-4-甲基苯胺。
本申请制备L5所得质量0.33g,产率70%。L5的氢谱和质谱如下:
1H NMR NMR(600MHz,CDCl3)δ8.47(d,J=4.5Hz,1H,Ar-H),7.93(d,J= 8.0Hz,1H,Ar-H),7.67–7.64(m,1H,Ar-H),7.34(d,J=8.3Hz,4H,Ar-H),7.27(d,J =6.9Hz,4H,Ar-H),7.26–7.22(m,1H,Ar-H),7.20(s,2H,Ar-H),2.42(s,3H,CH3), 1.86(s,3H,Ar-C(CH3)=N),1.27(s,18H,C(CH3)3).
APCI-MS(m/z):calcd for C34H39N2:475.3108,Found,475.3093,[M+H]+.
实施例6
利用实施例1-5中制备的N-三苯基亚胺吡啶配体L1、L2、L3、L4和L5分别与镍化合物(DME)NiBr2反应,制备得到N-三苯基亚胺吡啶镍配合物Ni1、 Ni2、Ni3、Ni4和Ni5。
制备方法为:在氮气氛围下,将0.2mmolN-三苯基亚胺吡啶配体(L1、L2、 L3 L4和L5)和(DME)NiBr2(62mg,0.2mmol)溶解在装有5mL二氯甲烷的施莱克瓶中,在室温下搅拌10h,随着搅拌进行,溶液的颜色逐渐加深。搅拌结束后,旋转蒸发器中减压下蒸发,得到固体,并用5ml己烷洗涤四次,然后真空干燥,得到所需的N-三苯基亚胺吡啶镍配合物(Ni1、Ni2、Ni3、Ni4和Ni5)。
其中,Ni1的结构式为:
Figure RE-GDA0003391003000000111
制备得到的Ni1质量为98mg,产率84%。Ni1的质谱如下:
MALDI-TOF MS(m/z):calcd for C26H22BrN2Ni:499.0320,Found:499.0328, [M-Br]+.Elemental analysis:calc.forC26H22Br2N2Ni:C,53.75;H,3.82;N,4.82. Found:C,53.84;H,3.79;N,4.87.
Ni2的结构式为:
Figure RE-GDA0003391003000000112
制备得到的Ni2质量为111mg,产率91%。Ni2的质谱如下:
MALDI-TOF MS(m/z):calcd for C28H26BrN2Ni:527.0633,Found:527.0651, [M-Br]+.Anal.Calcd for C28H26BrN2Ni:C,55.22;H,4.30;N,4.60.Found:C,55.12;H, 4.35;N,4.69.
Ni3的结构式为:
Figure RE-GDA0003391003000000113
制备得到的Ni3质量为110mg,产率89%。Ni3的质谱如下:
MALDI-TOFMS(m/z):calcdforC26H20BrF2N2Ni:535.0131,Found:535.0127,[M- Br]+.Elemental analysis:calc.for C26H20Br2F2N2Ni:C,50.62;H,3.27;N,4.54.Found: C,50.43;H,3.36;N,4.71.
Ni4的结构式为:
Figure RE-GDA0003391003000000121
制备得到的Ni4质量为116mg,产率94%。Ni4的质谱如下:
MALDI-TOFMS(m/z):calcd for C26H20BrCl2N2Ni:566.9540,Found:566.9538, [M-Br]+.Elemental analysis:calc.for C26H20Br2Cl2N2Ni:C,48.05;H,3.10;N,4.31. Found:C,48.25;H,3.14;N,4.51.
Ni5的结构式为:
Figure RE-GDA0003391003000000122
制备得到的Ni5质量为121mg,产率87%。Ni5的质谱如下:
ESI-MS(m/z):calcd for calcd for C34H38BrN2Ni:611.1572,Found:611.1581,[M- Br]+.Elemental analysis:calc.forC34H38Br2N2Ni:C,58.91;H,5.53;N,4.04.Found:C,58.85;H,5.64;N,4.11.
实施例7
利用实施例1-5中制备的N-三苯基亚胺吡啶配体L1、L2、L3、L4和L5分别与钯化合物Pd(COD)MeCl反应,制备得到N-三苯基亚胺吡啶钯配合物Pd1、 Pd2、Pd3、Pd4和Pd5。
制备方法为:在氮气氛围下,将0.5mmolN-三苯基亚胺吡啶配体(L1、L2、 L3、L4和L5)和Pd(COD)MeCl(133mg,0.5mmol)溶解在10mL二氯甲烷中,在室温下搅拌24h,随着搅拌进行,溶液的颜色逐渐加深。搅拌结束后,在旋转蒸发皿中减压蒸馏的直到看到少量固体产物。将混合物用20ml乙醚稀释,获得黄色沉淀,过滤收集黄色固体,并真空干燥,获得样品。
其中,Pd1的结构式为:
Figure RE-GDA0003391003000000131
本实施例制备的Pd1质量为236mg,产率91%。Pd1的氢谱和质谱如下:
1H NMR(600MHz,CDCl3)a-isomer:b-isomer=10:1δ9.11,8.97(d,J=4.4Hz, 1H,Ar-H),7.83(td,J=7.9,1.5Hz,1H,Ar-H),7.79,7.57(d,J=7.5Hz,4H,Ar-H), 7.53(d,J=7.9Hz,1H,Ar-H),7.49(dd,J=7.3,5.6Hz,1H,Ar-H),7.76,7.30(t,J= 7.7Hz,4H,Ar-H),7.36,7.23–7.20(m,4H,Ar-H),2.46(s,3H,CH3),2.02(s,3H,Ar- C(CH3)=N),0.66(s,3H,Pd-CH3).13C NMR(151MHz,CDCl3)δ173.77(C=N), 152.20,149.33,139.73,138.75,138.34,137.20,134.30,131.15,129.38,128.40, 128.14,127.59,124.55,21.04(CH3),19.45(Ar-C(CH3)=N),0.61(Pd-CH3).
MALDI-TOFMS(m/z):calcd for C26H22N2Pd:468.0818,Found:468.0791,[M- Me-Cl]+;calcd for C27H25N2Pd:483.1053,Found:483.1054,[M-Cl]+;calcd for C26H22ClN2Pd:503.0506,Found:503.0496,[M-Me]+.Elemental analysis:calc. forC27H25ClN2Pd:C,62.44;H,4.85;N,5.39.Found:C,62.35;H,4.67;N,5.41.
其中,Pd2的结构式为:
Figure RE-GDA0003391003000000141
本实施例制备的Pd2质量为253mg,产率92%。Pd2的氢谱和质谱如下:
1H NMR(600MHz,CDCl3)a-isomer:b-isomer=10:1δ9.19,9.02(d,J=4.9 Hz,1H,Ar-H),7.95,7.85(t,J=7.8Hz,1H,Ar-H),7.55(d,J=7.8Hz,1H,Ar-H), 7.52(dd,J=7.3,5.4Hz,1H,Ar-H),7.68,7.44(t,J=7.6Hz,4H,Ar-H),7.19(s,2H, Ar-H),7.15,7.09(d,J=7.8Hz,4H,Ar-H),2.44(s,3H,CH3),2.27(s,6H,Ar-CH3), 2.02(s,3H,Ar-C(CH3)=N),0.65(s,3H,Pd-CH3).13C NMR(151MHz,CDCl3)δ 173.57(C=N),152.31,149.38,139.74,138.22,137.18,137.01,135.88,134.24,131.01, 129.22,129.11,128.06,124.48,21.24(Ar-CH3),21.03(CH3),19.39(Ar-C(CH3)=N), 0.64(Pd-CH3).
ESI-MS(m/z):calcd for C28H26N2Pd:496.1131,Found:496.1134,[M-Me- Cl]+;calcd for C29H29N2Pd:511.1366,Found:511.1380,[M-Cl]+;calcd for C28H26N2ClPd:531.0819,Found:531.0808,[M-Me]+.Anal.Calcd forC29H29ClN2Pd: C,63.63;H,5.34;N,5.12.Found:C,63.58;H,5.47;N,5.27.
Pd3的结构式为:
Figure RE-GDA0003391003000000142
本实施例制备的Pd3质量为248mg,产率89%。Pd3的氢谱和质谱如下:
1H NMR a-isomer:b-isomer=10:11H NMR(600MHz,CDCl3)δ9.03,8.52(d, J=5.2Hz,1H,Ar-H),7.89(td,J=7.7,1.3Hz,1H,Ar-H),7.80–7.76(m,1H,Ar-H), 7.59(d,J=7.3Hz,1H,Ar-H),7.56(dd,J=7.7,4.5Hz,4H,Ar-H),7.20,7.12(s,2H, Ar-H),7.00(t,J=8.7Hz,4H,Ar-H),2.45,2.40(s,3H,CH3),2.00,1.88(s,3H,Ar- C(CH3)=N),0.97,0.64(s,3H,Pd-CH3).13C NMR(151MHz,CDCl3)δ173.86(C=N), 163.00,161.36,152.00,149.52,139.83,138.49,137.43,134.54,133.34,131.27, 131.08,131.03,128.43,124.68,115.57,115.42,21.00(CH3),19.37(Ar-C(CH3)=N), 0.67(Pd-CH3).19F NMR(565MHz,CDCl3)δ-114.00(s),-115.24(s).
ESI-MS(m/z):calcd for C26H20F2N2Pd:504.0629,Found:504.0635,[M-Me-Cl]+;calcd for C27H23F2N2Pd:519.0864,Found:519.0898,[M-Cl]+;calcd for C26H20ClF2N2Pd:539.0318,Found:539.0312,[M-Me]+.Anal.Calcd for C27H23ClF2N2Pd:C,58.39;H,4.17;N,5.04.Found:C,58.31;H,4.23;N,5.21.
Pd4的结构式为:
Figure RE-GDA0003391003000000151
本实施例制备的Pd4质量为266mg,产率90%。Pd4的氢谱和质谱如下:
1H NMR a-isomer:b-isomer=10:11H NMR(600MHz,CDCl3)δ9.20,9.04(d, J=4.7Hz,1H,Ar-H),8.54,7.89(d,J=5.2Hz,1H,Ar-H),7.76(dd,J=21.2,8.3Hz, 1H,Ar-H),7.59(t,J=6.5Hz,1H,Ar-H),7.55(d,J=8.5Hz,4H,Ar-H),7.28(d,J= 8.8Hz,4H,Ar-H),7.20(s,2H,Ar-H),2.45,2.40(s,3H,CH3),2.00,1.87(s,3H,Ar- C(CH3)=N),0.99,0.64(s,3H,Pd-CH3).13C NMR(151MHz,CDCl3)δ173.98(C=N), 151.90,149.58,139.68,138.51,137.56,137.00,133.80,133.18,131.39,131.24, 130.66,128.74,128.53,128.23,124.82,20.99(CH3),19.37(Ar-C(CH3)=N),0.64(Pd- CH3).
MALDI-TOFMS(m/z):calcd for C26H20Cl2N2Pd:536.0038,Found:536.0032, [M-Me-Cl]+;calcd for C27H23Cl2N2Pd:553.0277,Found:553.0309,[M-Cl]+;calcd forC26H20Cl3N2Pd:570.9727,Found:570.9746,[M-Me]+.Elemental analysis:calc.forC27H23Cl3N2Pd:C,55.13;H,3.94;N,4.76.Found:C,55.24;H,4.12;N,4.87.
Pd5的结构式为:
Figure RE-GDA0003391003000000161
本实施例制备的Pd5质量为0.275g,产率87%。Pd5的氢谱和质谱如下:
1H NMR(600MHz,CDCl3)δ8.94(d,J=4.6Hz,1H,Ar-H),7.81(td,J=7.8, 1.4Hz,1H,Ar-H),7.58–7.54(m,4H,Ar-H),7.53(d,J=7.6Hz,1H,Ar-H),7.45(dd, J=7.1,5.6Hz,1H,Ar-H),7.33–7.31(m,4H,Ar-H),7.20(s,2H,Ar-H),2.43(s,3H, CH3),2.01(s,3H,Ar-C(CH3)=N),1.24(s,18H,C(CH3)3),0.68(s,3H,Pd-CH3).13C NMR(151MHz,CDCl3)δ173.71(C=N),152.30,150.33,149.22,139.88,138.22, 136.95,135.86,134.09,131.11,129.10,128.06,125.27,124.42,34.58(C(CH3)3), 31.33(C(CH3)3),21.01(CH3),19.46(Ar-C(CH3)=N),0.56(Pd-CH3).
ESI-MS(m/z):calcd for C34H38N2Pd:580.2070,Found:580.2058,[M-Me-Cl]+;calcd for C35H41N2Pd:595.2305,Found:595.2377,[M-Cl]+;calcd for C34H38N2ClPd:615.1758,Found:615.1751,[M-Me]+.Anal.Calcd for C35H41N2ClPd:C,66.56;H,6.54; N,4.44.Found:C,66.45;H,6.38;N,4.29.
实施例8
利用实施例6制备的N-三苯基亚胺吡啶镍配合物Ni1、Ni2、Ni3、Ni4和 Ni5为催化剂进行乙烯均聚,方法为:
首先在真空90℃下干燥一台连接高压气体管路的350mL不锈钢压力反应器,干燥时间至少为1h;然后将反应器调整到所需的聚合温度(本实验实施温度为30℃、50℃和70℃)。在氮气气氛下向反应器中加入20mL甲苯以及所需量的氯化二乙基铝Et2AlCl,然后通过注射器将含所需N-三苯基亚胺吡啶镍催化剂的1mL二氯甲烷溶液注入聚合体系中,本实施例中催化剂加入量为1μmol。快速搅拌后,反应器加压并保持在6atm的乙烯状态。在所需的时间后,将压力反应器放空,将聚合物在真空下干燥过夜。
上述催化反应中,Ni1、Ni2、Ni3、Ni4和Ni5分别在30℃、50℃和70℃条件下进行1次,对各组的催化聚合物产物进行测试,测得各项数据如下表1 所示。表中Ni0项为对照组数据,对照数据使用含二亚胺配合体Ni催化剂,记为Ni0,其结构式表示如下:
Figure RE-GDA0003391003000000171
对照数据在50℃、70℃下聚合,其他反应条件同试验组,在最优化聚合条件下进行。
聚合物的分子量和分子量分布均通过凝胶渗透色谱法(GPC),以四氢呋喃溶剂在40℃的条件下测定,并使用聚苯乙烯为标准进行校准。
表1 Ni1、Ni2、Ni3、Ni4和Ni5催化聚合产物比较
Figure RE-GDA0003391003000000172
Figure RE-GDA0003391003000000181
本申请制备的N-三苯基亚胺吡啶镍配合物显示出非常高的乙烯齐聚活性(Act.b)5.5-7.8*106g·mol-1·h-1;用Ni1-Ni5做催化剂制备的乙烯低聚物分子量低 (约1-2kg/mol),分枝度高(69-100/1000C),呈蜡状或油状。从表1中可以看出,本申请制备的N-三苯基亚胺吡啶镍配合物Ni1、Ni2、Ni3、Ni4和Ni5的催化活性Act.b和分枝密度均随温度升高而先增后降,聚合温度对催化效果具有影响;随温度的升高,聚乙烯的分子量Mn c降低,说明生成了低分子量的高支链聚乙烯。对照组生成的聚乙烯对比Ni1-Ni5,分子量更小,活性更低,其得到的聚乙烯分枝密度Be差异较小,说明受聚合温度影响较小,这主要是因为在N-三苯基亚胺吡啶镍配合物体系中,温度的升高,链的行走和转移速度大于链的生长速度。此外,对照组催化剂生成相当支化度(80/1000C)低分支密度的聚乙烯,所获得的聚乙烯分子量分布范围PDI=Mw/Mn d分布在1.5-1.6之间,而Ni1、Ni2、 Ni3、Ni4和Ni5生成的高支化聚乙烯,其分子量分布范围PDI仅在1.32-1.46之间,同时催化剂对乙烯齐聚具有良好的热稳定性,表明本申请的N-三苯基亚胺吡啶镍配合物体系可以显著地影响聚合物的微观结构。
实施例9
利用实施例5制备的N-三苯基亚胺吡啶钯配合物Pd1-Pd5作为催化剂进行乙烯均聚,方法为:
首先在真空90℃下干燥一台连接高压气体管路的350mL不锈钢压力反应器,干燥时间至少为1h;然后将反应器调整到所需的聚合温度(本实验实施温度为30℃、50℃和70℃)。在氮气气氛下向反应器中加入20mL甲苯以及所需量的Et2AlCl,然后通过注射器将含所需N-三苯基亚胺吡啶镍催化剂的1mL二氯甲烷溶液注入聚合体系中,本实施例中催化剂加入量为1μmol。快速搅拌后,反应器加压并保持在6atm的乙烯状态。在所需的时间后,将压力反应器放空,将聚合物在真空下干燥过夜。
上述催化反应中,Pd1、Pd2、Pd3、Pd4和Pd5分别在30℃和50℃条件下进行1次,则试验分别得到Pd1、Pd2、Pd3、Pd4和Pd5催化剂的10份催化聚合物产物,测得聚聚合物产物的各项数据如下表2所示。表中Pd0项为对照组数据,Pd0结构式表示如下:
Figure RE-GDA0003391003000000191
对照数据在30℃、50℃下聚合,其他反应条件同试验组,在最优化聚合条件下进行。
表2 Pd1、Pd2、Pd3、Pd4和Pd5催化聚合产物比较
Figure RE-GDA0003391003000000192
从表2中可以看出,Pd1-Pd5作为催化剂进行乙烯均聚,得到的乙烯低聚物的活性和支化度随温度的升高而显著增加,分子量则稍有降低。这一趋势突出表明,高温有利于链转移和链行走反应,同时也增加了乙烯插入的速率。从表 2中可以看出,具有吸电子取代基的催化剂Pd3和Pd4生成了分子量较低、支化度较低(最高为146/1000C和148/1000C)的乙烯低聚物。具有供电子和体积较大的tBu基团的催化剂Pd5在50℃下生成了分子量大、支化度很高 (154/1000C)的乙烯低聚物。因此,以本申请制备的Pd1-Pd5作为催化剂,通过调整聚合温度和精确调控催化剂中杂化苯胺基团的电子效应和空间位阻,可以获得高支化程度和高插入比的烯烃共聚合物。
对照组生成的聚乙烯,在同样的聚合条件下,除了活性较好之外,所获得的低分子量烯烃聚合物分子量更小,支化程度在30℃下为106/1000C,50℃下为124/1000C,远低于使用本申请制备的Ni1-Ni5。
实施例10
利用实施例4制备的N-三苯基亚胺吡啶钯配合物Pd1-Pd5作为催化剂将丙烯酸甲酯与乙烯共聚,试验方法为:
首先在真空90℃下干燥一台连接高压气体管路的350mL不锈钢压力反应器,干燥时间至少为1h;然后将反应器调整到所需的聚合温度(本实验实施温度为30℃),在氮气气氛下向反应器中加入18mL的二氯甲烷与极性单体的混合溶液和所需量的NaBArF(本实施例中的NaBArF加入量为0.04mmol,极性单体为1mol/L),然后通过注射器将2mL含所需N-三苯基亚胺吡啶钯配合物的二氯甲烷溶液注入聚合体系(本实施例中催化剂加入量为0.02mmol)中。在快速搅拌后,共聚反应12h后,将压力反应器放空,然后将聚合物在真空下干燥过夜。
上述催化反应中,Pd1-Pd5分别在30℃条件下进行,则试验分别得到Pd1、 Pd2、Pd3、Pd4和Pd5五份催化剂的5份催化聚合物产物,测得聚合物产物的各项数据如下表2所示。表中Pd0项为对照组数据。
表3 Pd1、Pd2、Pd3、Pd4和Pd5催化聚合产物比较
Figure RE-GDA0003391003000000201
Figure RE-GDA0003391003000000211
插入比是极性丙烯酸酯类单体占所有单体的比值,与功能化聚乙烯关系密切。由表3可以看出,在乙烯-MA共聚反应中,Pd1、Pd2、Pd3、Pd4和Pd5的产物中,具有吸电子取代基的催化剂Pd3-Pd4,共聚活性Act.b高,但是E-MA 齐共聚物分子量和掺入比均降低。具有供电子和大空间位阻的催化剂Pd5共聚活性适中,得到分子量最大的高支化度E-MA低分子量共聚物,其掺入比也最高(高达8.92mol%)。从表3可以看出,亚胺吡啶Pd(II)催化剂可以高效地催化烯烃(乙烯或丙烯)和极性单体共聚反应,制备出一系列高插入比(2.6-8.9mol%)的超高度支化(144-151)的极性功能化的低分子量E-MA齐共聚物。结果表明,通过精确调控催化剂中杂化苯胺基团的电子效应和空间位阻,可以获得高支化程度和高插入比的烯烃共聚合物。进一步研究发现,N-三苯基亚胺吡啶钯配合物有利于长链和枝上枝的拓扑结构产生,所有长枝结构的比例高达87%,催化产生的共聚物的甲基支很少(13-16%)。这表明钯化合物比相应的镍化合物能进行更深入的链异构化,并给出更拓扑的分子结构。
而对照组中虽然活性较高,但产物插入比和支化度相对较低。在分子量相当的情况下,分支化度仅为120/1000C,极性基团的插入比仅1.73mol%左右。说明本发明提供的N-三苯基亚胺吡啶钯配合物作为催化剂具有很好地催化高插入比和高支化度的烯烃共聚反应的能力。进一步研究发现,齐聚温度不仅影响乙烯齐聚物的总分枝量,而且影响齐聚物的分枝分布。低聚温度越高,乙烯低聚物的长链分枝比例越高,尤其是分枝上的基团,说明该体系的过分枝可以由温度调节。
以上实施方式仅用以说明本发明的技术方案,而并非对本发明的限制;尽管参照前述实施方式对本发明进行了详细的说明,本领域的普通技术人员应当理解:凡在本发明创造的精神和原则之内所作的任何修改、等同替换和改进等,均应包含在本发明创造的保护范围之内。

Claims (10)

1.N-三苯基亚胺吡啶配体,该N-三苯基亚胺吡啶配体的结构式如式(Ⅰ)所示:
Figure FDA0003325017110000011
其中,R为氢-H、甲基-CH3、氯-Cl、氟-F和叔丁基-tBu中的任意一种。
2.如权利要求1所述的N-三苯基亚胺吡啶配体的制备方法,其特征在于,步骤如下:
S1.在圆底烧瓶中放入0.5-4N的ZnCl2、10-50N的2-乙酰吡啶和3-10mL冰醋酸的悬浮液,加入0.8-3N的2,6-二-(4-R-苯基)-4-甲基苯胺同类物,加热搅拌回流1-6h,冷却至室温;N为当量值;
S2.S1中溶液冷却至室温,沉淀出亮黄色固体,过滤并分离所述亮黄色固体,依次使用乙酸和乙醚洗涤后,在真空下干燥得到橘红色提纯固体;
S3.将所述橘红色提纯固体放入盛有10-60mL二氯甲烷的圆底烧瓶中,加入1-6N草酸钾水溶液3-20mL,并以1000-2000r/min速度搅拌30-80min;
S4.搅拌后溶液进行两相分离,水洗有机溶剂层,并用MgSO4干燥除去有机溶剂层水,再减压过滤;
S5.过滤后在真空干燥箱中去除溶剂,得到产物即为所需的N-三苯基亚胺吡啶配体。
3.如权利要求2所述的N-三苯基亚胺吡啶配体的制备方法,其特征在于,所述2,6-二-(4-R-苯基)-4-甲基苯胺同类物的制备方法,具体步骤为:
S11.氮气气氛下,将10-30N的4-R-苯基硼酸、5-20N的2,6-二溴-4-甲基-苯胺、1-2N的四(三苯基膦)钯Pd(PPh3)4和30-100N的K2CO3的混合物加入四氢呋喃与水的混合物液中,再将混合物液加热至65-80℃,搅拌18-36h;四氢呋喃与水以4:1~6:1体积比混合;
S12.将反应后的混合物液转移到旋转蒸发器中,去除溶剂,并用二氯甲烷提取残渣,继续转移到分液漏斗,加入水,震荡后静置分离出下层有机相,并用MgSO4干燥所述有机相;
S13过滤除去MgSO4固体,将有机相转移到旋转蒸发器中浓缩,浓缩液通过硅胶柱层析分离,分离得到的第二个组分即为2,6-二-(4-R-苯基)-4-甲基苯胺同类物。
4.一种N-三苯基亚胺吡啶镍配合物,其特征在于,所述配合物由权利要求1所述的N-三苯基亚胺吡啶配体与镍化合物形成,所述镍化合物为(DME)NiBr2,所述配合物的结构式如式(Ⅱ)所示:
Figure FDA0003325017110000021
其中,R为氢-H、甲基-CH3、氯-Cl、氟-F或叔丁基-tBu中的任意一种。
5.如权利要求4所述的N-三苯基亚胺吡啶镍配合物的制备方法,其特征在于,该制备方法为:在氮气氛围下,将N-三苯基亚胺吡啶配体和(DME)NiBr2按摩尔比1:(0.5-2)混合并溶解在二氯甲烷或三氯甲烷中,室温下搅拌反应6-24h;搅拌结束后,在旋转蒸发器皿中采用减压蒸馏方式得到固体产物,并将所述固体产物用乙烷洗涤,真空干燥得到所需的N-三苯基亚胺吡啶镍配合物。
6.一种N-三苯基亚胺吡啶钯配合物,其特征在于,所述配合物由权利要求1所述的N-三苯基亚胺吡啶配体与钯化合物形成,所述钯化合物为(COD)PdMeCl,所述配合物的结构式如式(Ⅲ)所示:
Figure FDA0003325017110000031
其中,R为氢-H、甲基-CH3、氯-Cl、氟-F或叔丁基-tBu中的任意一种。
7.如权利要求6所述的N-三苯基亚胺吡啶钯配合物的制备方法,其特征在于,该制备方法为:在氮气氛围下,将N-三苯基亚胺吡啶配体和(COD)PdMeCl按摩尔比1:(0.5-2)混合并溶解在二氯甲烷或三氯甲烷中,室温下搅拌反应12-48h;搅拌结束后,在旋转蒸发器皿中采用减压蒸馏方式直至观察到开始出现固体产物;停止旋蒸,在剩余惰性溶剂和固体产物中加入10-50ml乙醚稀释,得到黄色沉淀物;过滤并真空干燥该黄色沉淀物,即得到所需的N-三苯基亚胺吡啶钯配合物。
8.一种权利要求4所述的N-三苯基亚胺吡啶镍配合物或权利要求6所述的N-三苯基亚胺吡啶钯配合物作为烯烃聚合反应的催化剂的应用。
9.如权利要求8所述的应用,其特征在于,所述应用具体为:N-三苯基亚胺吡啶镍配合物对乙烯、丙烯或α-烯烃中的任意一种或多种进行催化聚合,得到分子量在1000-2000g/mol,枝化度在69-100/1000C的聚烯烃。
10.如权利要求8所述的应用,其特征在于,所述应用具体为:N-三苯基亚胺吡啶钯配合物对乙烯、丙烯或α-烯烃中任意一种或多种进行催化聚合,得到分子量在260-800g/mol,枝化度在127-165/1000C的聚烯烃;
或所述N-三苯基亚胺吡啶钯配合物对烯烃与丙烯酸酯类化合物进行催化共聚,得到分子量为260-787g/mol,且插入比大于10mol%的烯烃-丙烯酸酯类共聚物;所述丙烯酸酯类化合物为丙烯酸甲酯。
CN202111259158.7A 2021-10-28 2021-10-28 一种n-三苯基亚胺吡啶配体及其镍和钯配合物及配合物的制备与应用 Pending CN114195706A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111259158.7A CN114195706A (zh) 2021-10-28 2021-10-28 一种n-三苯基亚胺吡啶配体及其镍和钯配合物及配合物的制备与应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111259158.7A CN114195706A (zh) 2021-10-28 2021-10-28 一种n-三苯基亚胺吡啶配体及其镍和钯配合物及配合物的制备与应用

Publications (1)

Publication Number Publication Date
CN114195706A true CN114195706A (zh) 2022-03-18

Family

ID=80646438

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111259158.7A Pending CN114195706A (zh) 2021-10-28 2021-10-28 一种n-三苯基亚胺吡啶配体及其镍和钯配合物及配合物的制备与应用

Country Status (1)

Country Link
CN (1) CN114195706A (zh)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10324709A (ja) * 1997-03-21 1998-12-08 Mitsui Chem Inc オレフィン重合用触媒およびオレフィンの重合方法
CN102766087A (zh) * 2012-06-29 2012-11-07 中国科学院化学研究所 一种含有二苯甲基取代亚胺吡啶镍配合物及其制备方法与应用
CN103214504A (zh) * 2013-04-17 2013-07-24 哈尔滨工业大学 发绿光的邻吡啶单亚胺配体汞配合物及其制备方法
CN112920300A (zh) * 2021-02-01 2021-06-08 中国科学院长春应用化学研究所 一类大位阻α-二亚胺配体、镍催化剂及其制备方法与应用
CN113135828A (zh) * 2021-04-16 2021-07-20 中国科学院长春应用化学研究所 一类基于刚性三联苯结构的芳香胺、α-二亚胺配体、镍催化剂及其制备方法与应用
CN113527190A (zh) * 2021-08-19 2021-10-22 安徽大学 一种吡啶亚胺配体、基于该配体的吡啶亚胺镍钯配合物及其在催化乙烯聚合反应中的应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10324709A (ja) * 1997-03-21 1998-12-08 Mitsui Chem Inc オレフィン重合用触媒およびオレフィンの重合方法
CN102766087A (zh) * 2012-06-29 2012-11-07 中国科学院化学研究所 一种含有二苯甲基取代亚胺吡啶镍配合物及其制备方法与应用
CN103214504A (zh) * 2013-04-17 2013-07-24 哈尔滨工业大学 发绿光的邻吡啶单亚胺配体汞配合物及其制备方法
CN112920300A (zh) * 2021-02-01 2021-06-08 中国科学院长春应用化学研究所 一类大位阻α-二亚胺配体、镍催化剂及其制备方法与应用
CN113135828A (zh) * 2021-04-16 2021-07-20 中国科学院长春应用化学研究所 一类基于刚性三联苯结构的芳香胺、α-二亚胺配体、镍催化剂及其制备方法与应用
CN113527190A (zh) * 2021-08-19 2021-10-22 安徽大学 一种吡啶亚胺配体、基于该配体的吡啶亚胺镍钯配合物及其在催化乙烯聚合反应中的应用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
C. ROSE KENNEDY等: "Regio- and Diastereoselective Iron-Catalyzed [4+4]-Cycloaddition of 1,3-Dienes.", 《J. AM. CHEM. SOC.》 *
GE,YOU等: "Synthesis of Branched Polyethylene and Ethylene-MA Copolymers Using Unsymmetrical Iminopyridyl Nickel and Palladium Complexes", 《ORGANOMETALLICS》 *
MOHSEN MOGHEISEH等: "Synthesis of LDPE Using Pyridineimine-Based Nickel (II) Bromide Complexes: Effect of Catalyst Bulkiness on Thermal, Structural, and Morphological Properties.", 《MACROMOLECULAR REACTION ENGINEERING》 *
SHUAIKANG LI等: "Highly efficient incorporation of polar comonomers in copolymerizations with ethylene using iminopyridyl palladium system.", 《JOURNAL OF CATALYSIS》 *
YU-WEI DONG等: "Luminescence properties of a Zn(ii) supramolecular framework: easily tunable optical properties by variation of the alkyl substitution of (E)-N-(pyridine-2-ylethylidyne)arylamine ligands.", 《RSC ADVANCES》 *

Similar Documents

Publication Publication Date Title
CN110317149B (zh) 大位阻柔性二亚胺配体、基于其的二亚胺镍和钯配合物及其催化应用
WO2003070790A1 (fr) Polymere cristallin d'$g(a)-olefine d'ordre superieur et son procede de production
US8404792B2 (en) Cyclobutene polymers and methods of making the same
CN108484809B (zh) 一种烯烃聚合催化剂
CN109956980B (zh) 亚乙基苊不对称α-二亚胺镍催化剂及其制备方法和应用
CN109762027A (zh) 一种对位含芳基取代的α-二亚胺镍配合物及其制备方法和应用
CN111233755A (zh) 吡啶亚胺配体、基于其的吡啶亚胺钯配合物及其催化应用
CN114195706A (zh) 一种n-三苯基亚胺吡啶配体及其镍和钯配合物及配合物的制备与应用
CN102775535B (zh) 多支链高分子
CN113527190B (zh) 一种吡啶亚胺配体、基于该配体的吡啶亚胺镍钯配合物及其在催化乙烯聚合反应中的应用
CN110790852A (zh) 直接催化聚合乙烯与1,2-二取代极性内烯烃的方法及其产物
CN113603611A (zh) 一种非对称苊基α-二亚胺配体及其钯配合物和该配合物的制备与应用
JP4781623B2 (ja) オレフィンブロック共重合体、及びその製造方法
CN114989216B (zh) 一种强供电子膦磺酸镍化合物及其应用
CN112521531B (zh) 一种烯烃聚合催化剂组分、其制备方法及烯烃聚合催化剂和聚合方法
WO2021164844A1 (en) Catalysts and process for olefins and polar vinyl monomers copolymerization and olefins homopolymerization
CN107827935B (zh) 一种具有丁二酮骨架的α-二亚胺镍配合物及其制备方法和应用
CN116253663A (zh) 含有柔性环烷基取代基的α-二亚胺配体、基于其的配合物及其催化应用
KR100446495B1 (ko) 극성 불포화 단량체의 중합촉매를 사용한 중합방법
WO2008015160A1 (en) Polymerisation catalyst system based on oxime-ether ligands
CN109852452B (zh) 一种抗低温合成发动机油及其制备方法
CN108383862B (zh) 一种茚并[2,1-b]吲哚基稀土金属配合物及其制备方法
CN108218901B (zh) 一种茚并[1,2-b]吲哚基稀土金属配合物及其制备方法
CN116836197A (zh) 含磺酸钠取代基的配体化合物、镍配合物、磷氧镍负载型催化剂及其应用
CN117903350A (zh) 水相介质中极性聚烯烃的制备方法和该方法得到的极性聚烯烃

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20220318